Balchem Corporation reports record sales

Record net earnings for the first quarter were $3.4 million, an increase of
$0.6 million, or 20.4% as compared with the same period last
year.

Commenting on 2007, Dino A. Rossi, President and CEO of Balchem, said “We
are very pleased with the overall performance of the business. The results
derived from the CMC acquisition highlights one of our recent acquisitions and
successful strategic initiatives, and allows us to build off of our strong base
of technology and business.

“Choline products, both human and animal, are
developing very nicely, and are now further complemented by the recently
announced acquisitions of certain Chinook and Akzo Nobel
assets.

“Consistent with our plan, we continue to invest in our
pharmaceutical initiative, where we spent approximately $0.2 million in the
quarter. We look to 2007 with strong double digit growth expectations from the
core and acquired businesses, including continued spending toward our
pharmaceutical objectives, for both sales and earnings.”

Segment
information
Balchem Corporation consists of three business
segments:

• ARC Specialty Products, which provides specialty-packaged chemicals
  for use in healthcare and other industries;

• Encapsulated/Nutritional Products
  segment provides proprietary microencapsulation and agglomeration solutions to a
  variety of applications in the food, pharmaceutical, human and animal nutrition
  marketplaces, and

• BCP Ingredients manufactures and supplies choline
  chloride and derivatives used primarily in the poultry and swine industries.